The European Commission approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer with ≥1% PD-L1 expression. This includes patients that have no EGFR, ALK, or ROS1 aberrations and whose tumors are metastatic or locally advanced and not candidates for definitive chemoradiation.
Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.
